Fortress Biotech (FBIO) Cash from Operations (2010 - 2025)
Fortress Biotech (FBIO) posted quarterly Cash from Operations of 12544000.0 for Q4 2025, up 2.81% year-over-year from 12200859.68 in Q4 2024, and down 105.3% quarter-over-quarter from 6110000.0 in Q3 2025.
Powered by 
Analysis
Fortress Biotech (FBIO) Cash from Operations (2010 - 2025) Analysis & Trends
Fortress Biotech's Cash from Operations history runs 16 years deep, the most recent figure standing at 12544000.0 for Q4 2025.
- In Q4 2025, Cash from Operations rose 2.81% year-over-year to 12544000.0; the TTM figure through Dec 2025 stood at 65777000.0 (up 17.97% YoY), while the FY2025 annual figure was 65777000.0, up 17.97% from the prior year.
- Cash from Operations for Q4 2025 stood at 12544000.0, down from 6110000.0 in the prior quarter.
- The five-year high for Cash from Operations was 6110000.0 in Q3 2025, with the low at 47844000.0 in Q4 2022.
- The 5-year median for Cash from Operations is 26473500.0 (2024), against an average of 28506700.0.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations plunged 116.06% in 2022, then soared 69.54% in 2025.
- Fortress Biotech's Cash from Operations stood at 38696000.0 in 2021, then retreated by 23.64% to 47844000.0 in 2022, then gained by 26.98% to 34935000.0 in 2023, then surged by 63.05% to 12907000.0 in 2024, then increased by 2.81% to 12544000.0 in 2025.
- Business Quant data shows FBIO's Cash from Operations at 12544000.0 in Q4 2025, 6110000.0 in Q3 2025, and 27560000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -12.54 Mn |
| Sep 30, 2025 | -6.11 Mn |
| Jun 30, 2025 | -27.56 Mn |
| Mar 31, 2025 | -19.56 Mn |
| Dec 31, 2024 | -12.91 Mn |
| Sep 30, 2024 | -20.06 Mn |
| Jun 30, 2024 | -21.84 Mn |
| Mar 31, 2024 | -25.39 Mn |
| Dec 31, 2023 | -34.94 Mn |
| Sep 30, 2023 | -16.78 Mn |
| Jun 30, 2023 | -33.29 Mn |
| Mar 31, 2023 | -43.22 Mn |
| Dec 31, 2022 | -47.84 Mn |
| Sep 30, 2022 | -43.27 Mn |
| Jun 30, 2022 | -41.42 Mn |
| Mar 31, 2022 | -46.86 Mn |
| Dec 31, 2021 | -38.70 Mn |
| Sep 30, 2021 | -21.70 Mn |
| Jun 30, 2021 | -34.46 Mn |
| Mar 31, 2021 | -21.69 Mn |